Tekla Capital Management’s Abiomed Inc ABMD Stock Holding History

Tekla Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,812	Closed	-$3.5M	–	222
2020 Q4	$3.5M	Sell	10,812 -1,400	-11%	-$387K	0.12%	136
2020 Q3	$3.38M	Sell	12,212 -3,582	-23%	-$1.03M	0.13%	120
2020 Q2	$3.81M	Sell	15,794 -13,722	-46%	-$2.76M	0.15%	117
2020 Q1	$4.29M	Sell	29,516 -3,200	-10%	-$531K	0.19%	96
2019 Q4	$5.58M	Hold	32,716	–	–	0.21%	94
2019 Q3	$5.82M	Hold	32,716	–	–	0.25%	75
2019 Q2	$8.52M	Buy	32,716 +8,730	+36%	+$2.32M	0.35%	65
2019 Q1	$6.85M	Buy	23,986 +11,636	+94%	+$3.87M	0.28%	77
2018 Q4	$4.01M	Buy	12,350 +8,600	+229%	+$2.99M	0.17%	96
2018 Q3	$1.69M	Buy	+3,750	New	+$1.48M	0.06%	164
2018 Q2	–	Sell	-6,514	Closed	-$1.9M	–	191
2018 Q1	$1.9M	Buy	+6,514	New	+$1.65M	0.07%	137

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Tekla Capital Management's ABMD Position: Q1 2021 in Review

Tekla Capital Management sold out of Abiomed Inc (ABMD) in Q1 2021, closing a stake of 10,812 shares — an estimated $3.5M sold.

Tekla Capital Management first reported a position in ABMD in Q1 2018 and held it in 11 quarters. The position peaked at $8.52M in Q2 2019. 487 funds tracked by Wall St. Rank hold ABMD as of Q1 2021.

Tekla Capital Management reported no remaining Abiomed Inc position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 10,812 Abiomed Inc shares in Q1 2021, an estimated $3.5M.
Tekla Capital Management first reported a position in Abiomed Inc in Q1 2018 and held it in 11 quarters.
Tekla Capital Management's Abiomed Inc position peaked at $8.52M in Q2 2019.
487 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.